These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37395256)

  • 1. Use of long-acting cabotegravir + rilpivirine during hemodialysis and solid organ transplantation.
    Rezzonico LF; Baldassari L; Peracchi F; Merli M; Puoti M; Rossotti R
    AIDS; 2023 Jul; 37(9):1491-1493. PubMed ID: 37395256
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-acting cabotegravir/rilpivirine for HIV-1 treatment: real-world evaluation of barriers to implementation.
    Wood BR; Kassaye SG; Gerstoft J
    AIDS; 2023 Mar; 37(4):689-691. PubMed ID: 36815522
    [No Abstract]   [Full Text] [Related]  

  • 3. HIV virologic response and baseline genotypic resistance in a long-acting cabotegravir/rilpivirine initiation program.
    Masich AM; Gomes D; Higginson RT; Morgan Z; Nixon D; Tran M; Winthrop E; Fulco PP
    AIDS; 2023 Aug; 37(10):1641-1642. PubMed ID: 37450631
    [No Abstract]   [Full Text] [Related]  

  • 4. Cabotegravir and Rilpivirine.
    Am J Health Syst Pharm; 2021 May; 78(11):925-931. PubMed ID: 33822851
    [No Abstract]   [Full Text] [Related]  

  • 5. Cabotegravir-rilpivirine treatment initiation in a nonvirologically suppressed patient.
    Barnett SK; Armas-Kolostroubis L; Sension M; Riedel DJ
    AIDS; 2022 Aug; 36(10):1475-1476. PubMed ID: 35876710
    [No Abstract]   [Full Text] [Related]  

  • 6. Contribution of cabotegravir + rilpivirine long-acting for the treatment of HIV-1 infection.
    Calleja-Hernández MÁ; Martinez-Sesmero JM; Vallejo-Aparicio LA; Hernández-Novoa B; Badia X
    Farm Hosp; 2022 Jul; 46(4):208-214. PubMed ID: 36183218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries.
    Steegen K; Chandiwana N; Sokhela S; Venter WDF; Hans L
    AIDS; 2023 May; 37(6):1009-1011. PubMed ID: 36779485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOBEC-Induced Mutations at Initiation of Cabotegravir + Rilpivirine for Two Patients Infected by HIV-1 Subtype CRF02: The Interest of Systematic Genotyping.
    Wembulua BS; Valin N; Lambert-Niclot S; Nerozzi-Banfi E; Chiarabini T; Meynard JL; Lacombe K
    J Acquir Immune Defic Syndr; 2023 Mar; 92(3):e17-e18. PubMed ID: 36729654
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
    Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
    Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monthly injectable cabotegravir/rilpivirine to manage HIV infection in adults.
    Blackwell CW; López Castillo H
    J Am Assoc Nurse Pract; 2022 Jul; 34(7):918-923. PubMed ID: 35580282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First Extended-Release Injectable Drug Therapy for HIV.
    Aschenbrenner DS
    Am J Nurs; 2021 May; 121(5):24-25. PubMed ID: 33872258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir-rilpivirine in clinical practice.
    Borghetti A; Farinacci D; Ciccullo A; Dusina A; Moschese D; Iannone V; D'Angelillo A; Lombardi F; Donne VD; Massaroni V; Visconti E; Tamburrini E; Di Giambenedetto S
    J Med Virol; 2022 Oct; 94(10):4970-4974. PubMed ID: 35638227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment.
    Alberton F; Nozza S; Raccagni AR; Galli L; Spagnuolo V; Bossolasco S; Cernuschi M; Canetti D; Hasson H; Castagna A; Gianotti N
    J Med Virol; 2023 Jan; 95(1):e28330. PubMed ID: 36415058
    [No Abstract]   [Full Text] [Related]  

  • 15. Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE).
    Czarnogorski M; Garris CP; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR
    J Int AIDS Soc; 2022 Sep; 25(9):e26003. PubMed ID: 36094142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
    Garris CP; Czarnogorski M; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR
    J Int AIDS Soc; 2022 Sep; 25(9):e26006. PubMed ID: 36097674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transient Viremia in Young Adults With HIV After the Switch to Long-Acting Cabotegravir and Rilpivirine: Considerations for Dosing Schedule and Monitoring.
    Rakhmanina N; Richards K; Adeline Koay WL
    J Acquir Immune Defic Syndr; 2023 Mar; 92(3):e14-e17. PubMed ID: 36480701
    [No Abstract]   [Full Text] [Related]  

  • 18. Human Immunodeficiency Virus Type 1 RNA Levels in Rectal and Seminal Compartments After Switching to Long-Acting Cabotegravir Plus Rilpivirine: A Longitudinal Study.
    Masiá M; Fernández-González M; Agulló V; Mascarell P; Padilla S; García-Abellán J; Gutiérrez F
    Clin Infect Dis; 2023 Feb; 76(3):e748-e751. PubMed ID: 35986671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
    Courlet P; Alves Saldanha S; Cavassini M; Marzolini C; Choong E; Csajka C; Günthard HF; André P; Buclin T; Desfontaine V; Decosterd LA
    J Mass Spectrom; 2020 Jun; 55(6):e4506. PubMed ID: 32160389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials.
    Czarnogorski M; Benn P; McCoig C; Nwafor T; Griffith S; Sutton K; Harrington C; Saggu P; Yague I; Williams W; Español CM; Goodchild J; Fricker J; Patel P; D'Amico R
    J Acquir Immune Defic Syndr; 2022 Oct; 91(2):157-161. PubMed ID: 36094481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.